This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APLS Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock About Apellis Pharmaceuticals Stock (NASDAQ:APLS) Get APLS alerts:Sign Up Key Stats Today's Range$41.03▼$41.0750-Day Range$16.97▼$41.1252-Week Range$16.10▼$41.14Volume68.61 million shsAverage Volume7.54 million shsMarket Capitalization$5.25 billionP/E Ratio40.23Dividend YieldN/APrice Target$35.72Consensus RatingHold Company Overview Apellis Pharmaceuticals, Inc., traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life. The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders. In addition to its ophthalmology programs, Apellis is advancing clinical candidates in hematology, including indications such as paroxysmal nocturnal hemoglobinuria (PNH), and in rare kidney diseases like C3 glomerulopathy. Its diversified pipeline reflects a strategy to address high-unmet-need populations across multiple therapeutic areas. Founded in 2003 and headquartered in Waltham, Massachusetts, Apellis operates with a global footprint, conducting clinical trials and engaging regulatory authorities in key markets including the United States, Europe and Asia. The company collaborates with research institutions and industry partners to enhance its discovery engine and advance its development candidates from preclinical studies through late-stage trials. Apellis is led by President and Chief Executive Officer Cedric Francois, who brings extensive experience in biotechnology and drug development. Under his leadership, the company continues to expand its scientific capabilities and pursue strategic initiatives aimed at delivering transformative therapies to patients worldwide.AI Generated. May Contain Errors. Read More Apellis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreAPLS MarketRank™: Apellis Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat, and ranked 685th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingApellis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on no strong buy ratings, 3 buy ratings, 18 hold ratings, and 1 sell rating.Downside RiskApellis Pharmaceuticals has a consensus price target of $35.72, representing about 12.9% downside from its current price of $41.03.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Apellis Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.14) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is 40.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is 40.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.00.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 12.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apellis Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.01% of the float of Apellis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently decreased by 24.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.25 News SentimentApellis Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Apellis Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders6.50% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apellis Pharmaceuticals' insider trading history. Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APLS Stock News HeadlinesTop Medical Stocks To Consider - May 21stMay 24 at 5:05 AM | americanbankingnews.comMid Cap Stocks To Watch Now - May 21stMay 24 at 5:05 AM | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 25 at 1:00 AM | Weiss Ratings (Ad)Best Pharmaceutical Stocks To Add to Your Watchlist - May 21stMay 24 at 5:05 AM | americanbankingnews.comBiogen Stock Slides After Trial Miss, But Analysts Stay Bullish (APLS)Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock...May 22 at 12:00 PM | marketbeat.comMid Cap Stocks To Follow Today - May 19thMay 21, 2026 | americanbankingnews.comPromising Mid Cap Stocks To Keep An Eye On - May 15thMay 17, 2026 | americanbankingnews.comTop Pharmaceutical Stocks To Add to Your Watchlist - May 14thMay 16, 2026 | americanbankingnews.comSee More Headlines APLS Stock Analysis - Frequently Asked Questions How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its earnings results on Thursday, May, 7th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.44. The firm earned $268.30 million during the quarter, compared to the consensus estimate of $208.91 million. Apellis Pharmaceuticals had a net margin of 12.06% and a trailing twelve-month return on equity of 39.71%. Does Apellis Pharmaceuticals have any subsidiaries? Apellis Pharmaceuticals subsidiaries include Potentia Pharmaceuticals, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., and more. When did Apellis Pharmaceuticals IPO? Apellis Pharmaceuticals (APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,714,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Top institutional shareholders of Apellis Pharmaceuticals include Dimensional Fund Advisors LP (1.05%), Healthcare of Ontario Pension Plan Trust Fund (0.94%), Bank of America Corp DE (0.93%) and Kryger Capital LLC (0.86%). Insiders that own company stock include Pascal Deschatelets, Alec Machiels, Cedric Francois, Mark Jeffrey Delong, Timothy Eugene Sullivan, Adam J Townsend, David O Watson, Caroline Baumal, Nur Nicholson, Lukas Scheibler, Jeffrey Eisele, James George Chopas, Karen Lewis and A Sinclair Dunlop. View institutional ownership trends. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apellis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today5/24/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLS CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees770Year Founded2009Price Target and Rating Average Price Target for Apellis Pharmaceuticals$35.72 High Price Target$52.00 Low Price Target$18.00 Potential Upside/Downside-12.9%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)$1.02 Trailing P/E Ratio40.23 Forward P/E RatioN/A P/E GrowthN/ANet Income$22.39 million Net Margins12.06% Pretax Margin12.23% Return on Equity39.71% Return on Assets13.20% Debt Debt-to-Equity Ratio0.87 Current Ratio3.63 Quick Ratio3.16 Sales & Book Value Annual Sales$1.11 billion Price / Sales4.75 Cash Flow$0.21 per share Price / Cash Flow196.33 Book Value$3.24 per share Price / Book12.66Miscellaneous Outstanding Shares128,021,000Free Float119,700,000Market Cap$5.25 billion OptionableOptionable Beta-0.24 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:APLS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
